{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:18:38Z","timestamp":1768580318994,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T00:00:00Z","timestamp":1509062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T00:00:00Z","timestamp":1509062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 012504"],"award-info":[{"award-number":["R01 012504"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 ES017582"],"award-info":[{"award-number":["R01 ES017582"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 ES023826"],"award-info":[{"award-number":["R01 ES023826"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 ES11810"],"award-info":[{"award-number":["P01 ES11810"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001082"],"award-info":[{"award-number":["UL1TR001082"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00408-017-0062-x","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T03:56:51Z","timestamp":1509076611000},"page":"103-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects"],"prefix":"10.1007","volume":"196","author":[{"given":"Brian J.","family":"Day","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Briana Q.","family":"Barkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6872-1769","authenticated-orcid":false,"given":"Lisa A.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,27]]},"reference":[{"issue":"3","key":"62_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s004200100237","volume":"74","author":"PK Henneberger","year":"2001","unstructured":"Henneberger PK et al (2001) Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health 74(3):167\u2013176","journal-title":"Int Arch Occup Environ Health"},{"issue":"3","key":"62_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ajim.20140","volume":"47","author":"CR Schuler","year":"2005","unstructured":"Schuler CR et al (2005) Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility. Am J Ind Med 47(3):195\u2013205","journal-title":"Am J Ind Med"},{"issue":"1","key":"62_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1164\/rccm.200402-190OC","volume":"171","author":"LS Newman","year":"2005","unstructured":"Newman LS et al (2005) Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med 171(1):54\u201360","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"62_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1080\/104732201750169570","volume":"16","author":"LA Maier","year":"2001","unstructured":"Maier LA (2001) Beryllium health effects in the era of the beryllium lymphocyte proliferation test. Appl Occup Environ Hyg 16(5):514\u2013520","journal-title":"Appl Occup Environ Hyg"},{"issue":"12","key":"62_CR5","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.rmed.2012.08.014","volume":"106","author":"LA Maier","year":"2012","unstructured":"Maier LA et al (2012) Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease. Respir Med 106(12):1810\u20131813","journal-title":"Respir Med"},{"issue":"5","key":"62_CR6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1165\/ajrcmb.10.5.8179912","volume":"10","author":"TW Bost","year":"1994","unstructured":"Bost TW et al (1994) Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-alpha and interleukin-6 but not interleukin-1 beta. Am J Respir Cell Mol Biol 10(5):506\u2013513","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"7","key":"62_CR7","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1164\/ajrccm.164.7.2012123","volume":"164","author":"LA Maier","year":"2001","unstructured":"Maier LA et al (2001) High beryllium-stimulated TNF-alpha is associated with the \u2212308 TNF-alpha promoter polymorphism and with clinical severity in chronic beryllium disease. Am J Respir Crit Care Med 164(7):1192\u20131199","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"62_CR8","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1164\/rccm.200707-1021OC","volume":"177","author":"DR Dobis","year":"2008","unstructured":"Dobis DR et al (2008) Modulation of lymphocyte proliferation by antioxidants in chronic beryllium disease. Am J Respir Crit Care Med 177(9):1002\u20131011","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"62_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1183\/09031936.00149607","volume":"32","author":"S Marchand-Adam","year":"2008","unstructured":"Marchand-Adam S et al (2008) Short- and long-term response to corticosteroid therapy in chronic beryllium disease. Eur Respir J 32(3):687\u2013693","journal-title":"Eur Respir J"},{"issue":"6","key":"62_CR10","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1378\/chest.126.6.2000","volume":"126","author":"A Sood","year":"2004","unstructured":"Sood A, Beckett WS, Cullen MR (2004) Variable response to long-term corticosteroid therapy in chronic beryllium disease. Chest 126(6):2000\u20132007","journal-title":"Chest"},{"issue":"3","key":"62_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncpgasthep0696","volume":"4","author":"OH Nielsen","year":"2007","unstructured":"Nielsen OH, Munck LK (2007) Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 4(3):160\u2013170","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"3","key":"62_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/0891-5849(96)00031-7","volume":"21","author":"DC Pearson","year":"1996","unstructured":"Pearson DC, Jourd\u2019heuil D, Meddings JB (1996) The anti-oxidant properties of 5-aminosalicylic acid. Free Radic Biol Med 21(3):367\u2013373","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"62_CR13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/BF01300752","volume":"36","author":"P Gionchetti","year":"1991","unstructured":"Gionchetti P et al (1991) Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci 36(2):174\u2013178","journal-title":"Dig Dis Sci"},{"issue":"5","key":"62_CR14","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1053\/gast.1997.v113.pm9352850","volume":"113","author":"M Sandoval","year":"1997","unstructured":"Sandoval M et al (1997) Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine. Gastroenterology 113(5):1480\u20131488","journal-title":"Gastroenterology"},{"issue":"2","key":"62_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0006-2952(92)90286-R","volume":"43","author":"H Allgayer","year":"1992","unstructured":"Allgayer H et al (1992) Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy. Biochem Pharmacol 43(2):259\u2013262","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"62_CR16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1165\/rcmb.2009-0150OC","volume":"43","author":"DR Dobis","year":"2010","unstructured":"Dobis DR et al (2010) Sulfasalazine and mesalamine modulate beryllium-specific lymphocyte proliferation and inflammatory cytokine production. Am J Respir Cell Mol Biol 43(4):458\u2013464","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"62_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473\u2013483","journal-title":"Med Care"},{"issue":"10","key":"62_CR18","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1172\/JCI0215846","volume":"110","author":"AP Fontenot","year":"2002","unstructured":"Fontenot AP et al (2002) Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease. J Clin Invest 110(10):1473\u20131482","journal-title":"J Clin Invest"},{"issue":"4","key":"62_CR19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1165\/rcmb.2004-0090OC","volume":"31","author":"RT Sawyer","year":"2004","unstructured":"Sawyer RT et al (2004) Beryllium-ferritin: lymphocyte proliferation and macrophage apoptosis in chronic beryllium disease. Am J Respir Cell Mol Biol 31(4):470\u2013477","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"62_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/0091-6749(91)90300-D","volume":"88","author":"MM Mroz","year":"1991","unstructured":"Mroz MM et al (1991) Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol 88(1):54\u201360","journal-title":"J Allergy Clin Immunol"},{"issue":"22","key":"62_CR21","doi-asserted-by":"publisher","first-page":"16582","DOI":"10.1074\/jbc.M109.090506","volume":"285","author":"HM Brechbuhl","year":"2010","unstructured":"Brechbuhl HM et al (2010) Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2. J Biol Chem 285(22):16582\u201316587","journal-title":"J Biol Chem"},{"issue":"Suppl 2","key":"62_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0773.1997.tb01944.x","volume":"81","author":"S Bondesen","year":"1997","unstructured":"Bondesen S (1997) Intestinal fate of 5-aminosalicylic acid: regional and systemic kinetic studies in relation to inflammatory bowel disease. Pharmacol Toxicol 81(Suppl 2):1\u201328","journal-title":"Pharmacol Toxicol"},{"issue":"6","key":"62_CR23","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1164\/ajrccm\/139.6.1479","volume":"139","author":"LS Newman","year":"1989","unstructured":"Newman LS et al (1989) Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis 139(6):1479\u20131486","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"62_CR24","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1164\/ajrccm.156.6.9610040","volume":"156","author":"SS Tinkle","year":"1997","unstructured":"Tinkle SS, Newman LS (1997) Beryllium-stimulated release of tumor necrosis factor-alpha, interleukin-6, and their soluble receptors in chronic beryllium disease. Am J Respir Crit Care Med 156(6):1884\u20131891","journal-title":"Am J Respir Crit Care Med"},{"key":"62_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fonc.2013.00181","volume":"3","author":"E Gurpinar","year":"2013","unstructured":"Gurpinar E, Grizzle WE, Piazza GA (2013) COX-Independent mechanisms of cancer chemoprevention by anti-inflammatory drugs. Front Oncol 3:181","journal-title":"Front Oncol"},{"issue":"6894","key":"62_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nature00858","volume":"418","author":"P Scaffidi","year":"2002","unstructured":"Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418(6894):191\u2013195","journal-title":"Nature"},{"issue":"10","key":"62_CR27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/embo-reports\/kvf198","volume":"3","author":"S Gardella","year":"2002","unstructured":"Gardella S et al (2002) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 3(10):995\u20131001","journal-title":"EMBO Rep"},{"issue":"28","key":"62_CR28","doi-asserted-by":"publisher","first-page":"12611","DOI":"10.1073\/pnas.1006542107","volume":"107","author":"H Yang","year":"2010","unstructured":"Yang H et al (2010) Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA 107(28):12611\u201312616","journal-title":"Proc Natl Acad Sci USA"},{"key":"62_CR29","doi-asserted-by":"publisher","first-page":"e1786","DOI":"10.1038\/cddis.2015.153","volume":"6","author":"H Yang","year":"2015","unstructured":"Yang H et al (2015) Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death Dis 6:e1786","journal-title":"Cell Death Dis"},{"issue":"9","key":"62_CR30","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1084\/jem.20120189","volume":"209","author":"E Venereau","year":"2012","unstructured":"Venereau E et al (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 209(9):1519\u20131528","journal-title":"J Exp Med"},{"issue":"2","key":"62_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.bcp.2010.10.001","volume":"81","author":"NS Gould","year":"2011","unstructured":"Gould NS, Day BJ (2011) Targeting maladaptive glutathione responses in lung disease. Biochem Pharmacol 81(2):187\u2013193","journal-title":"Biochem Pharmacol"},{"issue":"11\u201312","key":"62_CR32","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/j.1365-2036.2008.03854.x","volume":"28","author":"EJ Irvine","year":"2008","unstructured":"Irvine EJ et al (2008) The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis. Aliment Pharmacol Ther 28(11\u201312):1278\u20131286","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"62_CR33","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/j.1365-2036.2012.05107.x","volume":"35","author":"D Solomon","year":"2012","unstructured":"Solomon D et al (2012) The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients. Aliment Pharmacol Ther 35(12):1386\u20131396","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"62_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000103896","volume":"25","author":"G Comparato","year":"2007","unstructured":"Comparato G et al (2007) Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? Dig Dis 25(3):252\u2013259","journal-title":"Dig Dis"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-017-0062-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-017-0062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-017-0062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T10:03:02Z","timestamp":1628589782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-017-0062-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,27]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["62"],"URL":"https:\/\/doi.org\/10.1007\/s00408-017-0062-x","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,27]]},"assertion":[{"value":"29 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Brian Day declares that he has received research grants from the NIH and is an inventor on an issued US Patent for use of 5-ASA in the treatment of granulomatous lung disease. Dr. Lisa Maier has received research grants from the NIH. Dr. Jie Huang, Mrs. Briana Barkes, Mrs. May Gillespie, and Dr. Li Li declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the National Jewish Health institutional review board (IRB) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}